Capturing the primordial Kras mutation initiating urethane carcinogenesis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
14 04 2020
Historique:
received: 06 09 2019
accepted: 23 03 2020
entrez: 15 4 2020
pubmed: 15 4 2020
medline: 22 7 2020
Statut: epublish

Résumé

The environmental carcinogen urethane exhibits a profound specificity for pulmonary tumors driven by an oncogenic Q

Identifiants

pubmed: 32286309
doi: 10.1038/s41467-020-15660-8
pii: 10.1038/s41467-020-15660-8
pmc: PMC7156420
doi:

Substances chimiques

Protein Isoforms 0
Urethane 3IN71E75Z5
Hras protein, mouse EC 3.6.5.2
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1800

Subventions

Organisme : NCI NIH HHS
ID : P01 CA203657
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA094184
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM127062
Pays : United States

Références

You, M., Candrian, U., Maronpot, R. R., Stoner, G. D. & Anderson, M. W. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc. Natl Acad. Sci. USA 86, 3070–3074 (1989).
pubmed: 2654935 doi: 10.1073/pnas.86.9.3070
Forkert, P. G. Mechanisms of lung tumorigenesis by ethyl carbamate and vinyl carbamate. Drug Metab. Rev. 42, 355–378 (2010).
pubmed: 20205516 doi: 10.3109/03602531003611915
Westcott, P. M. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489–492 (2015).
pubmed: 25363767 doi: 10.1038/nature13898
Nuzum, E. O., Malkinson, A. M. & Beer, D. G. Specific Ki-ras codon 61 mutations may determine the development of urethan-induced mouse lung adenomas or adenocarcinomas. Mol. Carcinog. 3, 287–295 (1990).
pubmed: 2244961 doi: 10.1002/mc.2940030509
Dwyer-Nield, L. D. et al. Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/6J-ChrA/J chromosome substitution strains. Int. J. Cancer 126, 125–132 (2010).
pubmed: 19609923 pmcid: 2783521 doi: 10.1002/ijc.24743
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Disco. 13, 828–851 (2014).
doi: 10.1038/nrd4389
Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457–2467 (2012).
pubmed: 22589270 pmcid: 3354961 doi: 10.1158/0008-5472.CAN-11-2612
Hernandez, L. G. & Forkert, P. G. In vivo mutagenicity of vinyl carbamate and ethyl carbamate in lung and small intestine of F1 (Big Blue x A/J) transgenic mice. Int. J. Cancer 120, 1426–1433 (2007).
pubmed: 17205523 doi: 10.1002/ijc.22502
Fox, E. J., Reid-Bayliss, K. S., Emond, M. J. & Loeb, L. A. Accuracy of next generation sequencing platforms. Gener. Seq. Appl. 1, 1000106 (2014).
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl Acad. Sci. USA 108, 9530–9535 (2011).
pubmed: 21586637 doi: 10.1073/pnas.1105422108
Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508–14513 (2012).
pubmed: 22853953 doi: 10.1073/pnas.1208715109
Lou, D. I. et al. High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. Proc. Natl Acad. Sci. USA 110, 19872–19877 (2013).
pubmed: 24243955 doi: 10.1073/pnas.1319590110
Jee, J. et al. Rates and mechanisms of bacterial mutagenesis from maximum-depth sequencing. Nature 534, 693–696 (2016).
pubmed: 27338792 pmcid: 4940094 doi: 10.1038/nature18313
Blattner, F. R. et al. The complete genome sequence of Escherichia coli K-12. Science 277, 1453–1462 (1997).
pubmed: 9278503 doi: 10.1126/science.277.5331.1453
Waterston, R. H. et al. Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520–562 (2002).
pubmed: 12466850 doi: 10.1038/nature01262
Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604–8610 (2011).
pubmed: 22035192 pmcid: 3216358 doi: 10.1021/ac202028g
Fernando, R. C., Nair, J., Barbin, A., Miller, J. A. & Bartsch, H. Detection of 1,N
pubmed: 8761431 doi: 10.1093/carcin/17.8.1711
Forkert, P. G. et al. Oxidation of vinyl carbamate and formation of 1,N
pubmed: 17296623 doi: 10.1124/dmd.106.013805
Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
pubmed: 30371878 doi: 10.1093/nar/gky1015
Winters, I. P. et al. Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. Nat. Commun. 8, 2053 (2017).
pubmed: 29233960 pmcid: 5727199 doi: 10.1038/s41467-017-01519-y
Borrego, A. et al. Germline control of somatic Kras mutations in mouse lung tumors. Mol. Carcinog. 57, 745–751 (2018).
pubmed: 29500885 doi: 10.1002/mc.22796
Burd, C. E. et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Disco. 4, 1418–1429 (2014).
doi: 10.1158/2159-8290.CD-14-0729
Kiessling, M. K. et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget 6, 42183–42196 (2015).
pubmed: 26544513 pmcid: 4747218 doi: 10.18632/oncotarget.5619
Li, S., Balmain, A. & Counter, C. M. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat. Rev. Cancer 18, 767–777 (2018).
pubmed: 30420765 doi: 10.1038/s41568-018-0076-6
Dragani, T. A., Manenti, G. & Della Porta, G. Quantitative analysis of genetic susceptibility to liver and lung carcinogenesis in mice. Cancer Res. 51, 6299–6303 (1991).
pubmed: 1933890
Heston, W. E., Vlahakis, G. & Deringer, M. K. High incidence of spontaneous hepatomas and the increase of this incidence with urethan in C3H, C3Hf, and C3He male mice. J. Natl Cancer Inst. 24, 425–435 (1960).
pubmed: 14401531 doi: 10.1093/jnci/24.3.721
Guerra, C. et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291–302 (2007).
pubmed: 17349585 doi: 10.1016/j.ccr.2007.01.012
Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437–450 (2003).
pubmed: 14706336 doi: 10.1016/S1535-6108(03)00309-X
Grebe, S. K. & Singh, R. J. LC-MS/MS in the clinical laboratory—Where to from here? Clin. Biochem Rev. 32, 5–31 (2011).
pubmed: 21451775 pmcid: 3052391
Guengerich, F. P. & Kim, D. H. Enzymatic oxidation of ethyl carbamate to vinyl carbamate and its role as an intermediate in the formation of 1,N
pubmed: 1912327 doi: 10.1021/tx00022a003
Nomeir, A. A., Ioannou, Y. M., Sanders, J. M. & Matthews, H. B. Comparative metabolism and disposition of ethyl carbamate (urethane) in male Fischer 344 rats and male B6C3F1 mice. Toxicol. Appl. Pharm. 97, 203–215 (1989).
doi: 10.1016/0041-008X(89)90326-8
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pubmed: 3776390 pmcid: 3776390 doi: 10.1038/nature12477
Kucab, J. E. et al. A compendium of mutational signatures of environmental agents. Cell 177, 821–836 (2019).
pubmed: 6506336 pmcid: 6506336 doi: 10.1016/j.cell.2019.03.001
Haradhvala, N. J. et al. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell 164, 538–549 (2016).
pubmed: 26806129 pmcid: 4753048 doi: 10.1016/j.cell.2015.12.050
Newlaczyl, A. U., Coulson, J. M. & Prior, I. A. Quantification of spatiotemporal patterns of Ras isoform expression during development. Sci. Rep. 7, 41297 (2017).
pubmed: 28117393 pmcid: 5259795 doi: 10.1038/srep41297
Li, B. et al. A comprehensive mouse transcriptomic bodymap across 17 tissues by RNA-seq. Sci. Rep. 7, 4200 (2017).
pubmed: 28646208 pmcid: 5482823 doi: 10.1038/s41598-017-04520-z
Shen, Y. et al. A map of the cis-regulatory sequences in the mouse genome. Nature 488, 116–120 (2012).
pubmed: 4041622 pmcid: 4041622 doi: 10.1038/nature11243
Phallen, J. et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci. Transl. Med. 9, eaan2415 (2017).
pubmed: 28814544 pmcid: 6714979 doi: 10.1126/scitranslmed.aan2415
Ichikawa, T. et al. The activation of K-ras gene at an early stage of lung tumorigenesis in mice. Cancer Lett. 107, 165–170 (1996).
pubmed: 8947508 doi: 10.1016/0304-3835(96)04351-0
Yano, T., Yuasa, M., Murakami, A., Ichikawa, T. & Hagiwara, K. The detection of chemically initiated cells having the mutation of K-ras gene at an early stage of lung carcinogenesis in mice. Anal. Biochem. 244, 187–189 (1997).
pubmed: 9025932 doi: 10.1006/abio.1996.9902
Spella, M. et al. Club cells form lung adenocarcinomas and maintain the alveoli of adult mice. Elife 8, e45571 (2019).
pubmed: 31140976 pmcid: 6606035 doi: 10.7554/eLife.45571
van Mansfeld, A. D. & Bos, J. L. PCR-based approaches for detection of mutated ras genes. PCR Methods Appl. 1, 211–216 (1992).
pubmed: 1362126 doi: 10.1101/gr.1.4.211
Pender, A. et al. Efficient genotyping of KRAS mutant non-small cell lung cancer using a multiplexed droplet digital PCR approach. PLoS ONE 10, e0139074 (2015).
pubmed: 26413866 pmcid: 4586384 doi: 10.1371/journal.pone.0139074
Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006–1014 (2012).
pubmed: 22842228 pmcid: 3432702 doi: 10.1038/ng.2359
Pershing, N. L. et al. Rare codons capacitate Kras-driven de novo tumorigenesis. J. Clin. Invest. 125, 222–233 (2015).
pubmed: 25437878 doi: 10.1172/JCI77627
Huang, L., Carney, J., Cardona, D. M. & Counter, C. M. Decreased tumorigenesis in mice with a Kras point mutation at C118. Nat. Commun. 5, 5410 (2014).
pubmed: 25394415 pmcid: 4234187 doi: 10.1038/ncomms6410
Temko, D., Tomlinson, I. P. M., Severini, S., Schuster-Bockler, B. & Graham, T. A. The effects of mutational processes and selection on driver mutations across cancer types. Nat. Commun. 9, 1857 (2018).
pubmed: 29748584 pmcid: 5945620 doi: 10.1038/s41467-018-04208-6
Buisson, R. et al. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. Science 364, eaaw2872 (2019).
pubmed: 31249028 pmcid: 6731024 doi: 10.1126/science.aaw2872
Dietlein, F. et al. Identification of cancer driver genes based on nucleotide context. Nat. Genet. 52, 208–218 (2020).
pubmed: 32015527 doi: 10.1038/s41588-019-0572-y
Hancock, J. F. Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. 4, 373–384 (2003).
pubmed: 12728271 doi: 10.1038/nrm1105
Kovalski, J. R. et al. The functional proximal proteome of oncogenic Ras includes mTORC2. Mol. Cell 73, 830–44 e12 (2019).
pubmed: 30639242 pmcid: 6386588 doi: 10.1016/j.molcel.2018.12.001
Adhikari, H. & Counter, C. M. Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nat. Commun. 9, 3646 (2018).
pubmed: 30194290 pmcid: 6128905 doi: 10.1038/s41467-018-05692-6
Villalonga, P. et al. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol. Cell Biol. 21, 7345–7354 (2001).
pubmed: 11585916 pmcid: 99908 doi: 10.1128/MCB.21.21.7345-7354.2001
Elad-Sfadia, G., Haklai, R., Balan, E. & Kloog, Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J. Biol. Chem. 279, 34922–34930 (2004).
pubmed: 15205467 doi: 10.1074/jbc.M312697200
To, M. D. et al. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat. Genet. 40, 1240–1244 (2008).
pubmed: 18758463 pmcid: 2654781 doi: 10.1038/ng.211
McCreery, M. Q. & Balmain, A. Chemical carcinogenesis models of cancer: back to the future. Annu Rev. Cancer Biol. 1, 295–312 (2017).
doi: 10.1146/annurev-cancerbio-050216-122002
Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017).
pubmed: 28666118 pmcid: 5555610 doi: 10.1016/j.cell.2017.06.009
Stephen, A. G., Esposito, D., Bagni, R. K. & McCormick, F. Dragging ras back in the ring. Cancer Cell 25, 272–281 (2014).
pubmed: 24651010 doi: 10.1016/j.ccr.2014.02.017
Adar, S., Hu, J., Lieb, J. D. & Sancar, A. Genome-wide kinetics of DNA excision repair in relation to chromatin state and mutagenesis. Proc. Natl Acad. Sci. USA 113, E2124–E2133 (2016).
pubmed: 27036006 doi: 10.1073/pnas.1603388113
Hoffler, U. & Ghanayem, B. I. Increased bioaccumulation of urethane in CYP2E1−/− versus CYP2E1+/+ mice. Drug Metab. Dispos. 33, 1144–1150 (2005).
pubmed: 15879495 doi: 10.1124/dmd.105.003806
Supek, F. & Lehner, B. Clustered mutation signatures reveal that error-prone DNA repair targets mutations to active genes. Cell 170, 534–547 (2017).
pubmed: 28753428 doi: 10.1016/j.cell.2017.07.003
To, M. D. et al. A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat. Genet. 38, 926–930 (2006).
pubmed: 16823377 pmcid: 4461000 doi: 10.1038/ng1836
Dassano, A. et al. Mouse pulmonary adenoma susceptibility 1 locus is an expression QTL modulating Kras-4A. PLoS Genet. 10, e1004307 (2014).
pubmed: 24743582 pmcid: 3990522 doi: 10.1371/journal.pgen.1004307
Hanawalt, P. C. & Spivak, G. Transcription-coupled DNA repair: two decades of progress and surprises. Nat. Rev. Mol. Cell Biol. 9, 958–970 (2008).
pubmed: 19023283 doi: 10.1038/nrm2549
Zheng, C. L. et al. Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes. Cell Rep. 9, 1228–1234 (2014).
pubmed: 25456125 pmcid: 4254608 doi: 10.1016/j.celrep.2014.10.031
Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761–774 (2011).
pubmed: 21993244 pmcid: 3632399 doi: 10.1038/nrc3106
Haigis, K. M. KRAS alleles: the devil is in the detail. Trends Cancer 3, 686–697 (2017).
pubmed: 28958387 pmcid: 5824632 doi: 10.1016/j.trecan.2017.08.006
Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989).
pubmed: 2547513
Xu, X. et al. Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc. Natl Acad. Sci. USA 109, 4910–4915 (2012).
pubmed: 22411819 doi: 10.1073/pnas.1112499109
Morgenstern, J. P. & Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587–3596 (1990).
pubmed: 2194165 pmcid: 331014 doi: 10.1093/nar/18.12.3587
O’Hayer, K. M. & Counter, C. M. A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro. Methods Enzymol. 407, 637–647 (2006).
pubmed: 16757358 doi: 10.1016/S0076-6879(05)07050-3
Norrander, J., Kempe, T. & Messing, J. Construction of improved M13 vectors using oligodeoxynucleotide-directed mutagenesis. Gene 26, 101–106 (1983).
pubmed: 6323249 doi: 10.1016/0378-1119(83)90040-9
Afgan, E. et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res. 46, W537–W544 (2018).
pubmed: 29790989 pmcid: 6030816 doi: 10.1093/nar/gky379
Zhang, J., Kobert, K., Flouri, T. & Stamatakis, A. PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics 30, 614–620 (2014).
pubmed: 24142950 doi: 10.1093/bioinformatics/btt593
Arbeithuber, B., Makova, K. D. & Tiemann-Boege, I. Artifactual mutations resulting from DNA lesions limit detection levels in ultrasensitive sequencing applications. DNA Res. 23, 547–559 (2016).
pubmed: 27477585 pmcid: 5144678 doi: 10.1093/dnares/dsw038
Rowlands, V. et al. Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA. Sci. Rep. 9, 12620 (2019).
pubmed: 31477768 pmcid: 6718424 doi: 10.1038/s41598-019-49043-x
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408 (2001).
doi: 10.1006/meth.2001.1262

Auteurs

Siqi Li (S)

Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, 27710, USA.

David M MacAlpine (DM)

Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, 27710, USA.

Christopher M Counter (CM)

Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, 27710, USA. count004@mc.duke.edu.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH